Allianz Asset Management
HRMY icon

Allianz Asset Management’s Harmony Biosciences HRMY Stock Holding History

Allianz Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-220,704
Closed -$7.33M – 2144
2025
Q1 		$7.33M Buy
220,704
+208,504
+1,709% +$7.47M 0.01% 915
2024
Q4 		$420K Buy
+12,200
New +$419K ﹤0.01% 1916
2023
Q4 		– Sell
-23,800
Closed -$780K – 2183
2023
Q3 		$780K Hold
23,800
– – ﹤0.01% 1787
2023
Q2 		$838 Sell
23,800
-7,400
-24% -$255K ﹤0.01% 2049
2023
Q1 		$1.02M Buy
31,200
+12,100
+63% +$551K ﹤0.01% 1679
2022
Q4 		$1.05M Buy
+19,100
New +$1.05M ﹤0.01% 1507

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allianz Asset Management's HRMY Position: Q2 2025 in Review

Allianz Asset Management sold out of Harmony Biosciences (HRMY) in Q2 2025, closing a stake of 220,704 shares — an estimated $7.33M sold.

Allianz Asset Management first reported a position in HRMY in Q4 2022 and held it in 6 quarters. The position peaked at $7.33M in Q1 2025. 279 funds tracked by Wall St. Rank hold HRMY as of Q2 2025.

  • Allianz Asset Management reported no remaining Harmony Biosciences position as of Q2 2025 after selling out during the quarter.
  • Allianz Asset Management sold 220,704 Harmony Biosciences shares in Q2 2025, an estimated $7.33M.
  • Allianz Asset Management first reported a position in Harmony Biosciences in Q4 2022 and held it in 6 quarters.
  • Allianz Asset Management's Harmony Biosciences position peaked at $7.33M in Q1 2025.
  • 279 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2025.

Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.